Journal of Medicinal Chemistry · 2005 · 63 citations · 28 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsDrug-receptor InteractionsPotency OptimizationReceptor Pharmacology5-Hydroxytryptamine 3 Receptor Antagonists5-Hydroxytryptamine Receptor PharmacologyHistamine Receptor AntagonismHistamine Receptor AntagonistsHistamine Receptor PharmacologyHistamine ReceptorsIn Vivo Efficacy TestingPotency Assays
A new series of H3 receptor antagonists was discovered with nanomolar and subnanomolar affinities at human and rat H3 receptors. Starting from an earlier, more structurally limited series of benzofurans, the present series of compounds demonstrated increased structural variety and flexibility with greater in vitro potency. One compound in particular, [2-[2-(2-(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl](5-nitropyridin-2-yl)amine (7h), gave the best binding potency (human K(i) of 0.05 nM, rat K(i) of 0.11 nM), which represented a 9-fold (in human) and an 11-fold (in rat) improvement over ABT-239 (compound 5), a compound previously reported to have excellent in vitro potency and in vivo efficacy. The synthesis, SAR of the H3 binding affinities, in vitro assay for phospholipidosis, and pharmacokinetic properties of the new compounds are described.
28